device implantation as a transition to long-term warfarin therapy. We retrospectively
evaluated the effects of heparin use on thromboembolic and bleeding complications after
implantation of the HeartMate II left ventricular assist device (LVAD). METHODS: LVAD
patients (n= 418) implanted as a bridge to transplant were divided into three groups: Group
A patients (therapeutic, n= 118) received heparin and had a partial thromboplastin time …